Get startedLog in
    Picture of Sage Therapeutics logo

    SAGE — Sage Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapMomentum Trap
    All News

    Brief: Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)

    Picture of Sage Therapeutics logoSage Therapeutics
    20/11/2024 11:32
    Nov 20 (Reuters) - SAGE Therapeutics Inc  SAGE.O :
    * SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE
2
DIMENSION STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF
COGNITIVE IMPAIRMENT ASSOCIATED WITH HUNTINGTON’S DISEASE
    * SAGE THERAPEUTICS INC - DALZANEMDOR DID NOT MEET PRIMARY
ENDPOINT IN PHASE 2 STUDY
    * SAGE THERAPEUTICS INC - DALZANEMDOR GENERALLY
WELL-TOLERATED
WITH NO NEW SAFETY SIGNALS
    * SAGE THERAPEUTICS INC - TO HALT FURTHER DEVELOPMENT OF
DALZANEMDOR
    * SAGE THERAPEUTICS - TO CLOSE ONGOING PURVIEW STUDY, AN
OPEN-LABEL SAFETY STUDY OF DALZANEMDOR IN PARTICIPANTS WITH HD

Source text:  ID:nBw3XvSsba 
Further company coverage:  SAGE.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Sage Therapeutics

    See all news